Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Solid Biosciences (SLDB)

Solid Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SLDB
DateTimeSourceHeadlineSymbolCompany
20/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLDBSolid Biosciences Inc
15/05/202413:26Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SLDBSolid Biosciences Inc
15/05/202412:52GlobeNewswire Inc.Solid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
15/05/202412:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLDBSolid Biosciences Inc
07/05/202412:00GlobeNewswire Inc.Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:SLDBSolid Biosciences Inc
06/05/202423:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
02/05/202421:05GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
03/04/202421:05GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
01/04/202412:45GlobeNewswire Inc.Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
27/03/202411:00GlobeNewswire Inc.Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumNASDAQ:SLDBSolid Biosciences Inc
13/03/202411:44GlobeNewswire Inc.Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
07/03/202412:00GlobeNewswire Inc.Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDNASDAQ:SLDBSolid Biosciences Inc
06/03/202413:00GlobeNewswire Inc.Solid Biosciences to Participate at Upcoming Investor ConferencesNASDAQ:SLDBSolid Biosciences Inc
16/02/202417:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202416:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202416:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202416:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202416:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202415:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
09/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLDBSolid Biosciences Inc
30/01/202422:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
30/01/202421:09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLDBSolid Biosciences Inc
20/01/202400:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/01/202413:50Dow Jones NewsSolid Biosciences Gets Orphan Drug Designation for SGT-003NASDAQ:SLDBSolid Biosciences Inc
16/01/202413:00GlobeNewswire Inc.Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
12/01/202422:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SLDBSolid Biosciences Inc
11/01/202422:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
10/01/202421:31Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SLDBSolid Biosciences Inc
08/01/202412:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLDBSolid Biosciences Inc
08/01/202412:09GlobeNewswire Inc.Solid Biosciences Announces $109 Million Private PlacementNASDAQ:SLDBSolid Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SLDB

Your Recent History

Delayed Upgrade Clock